PTPRC and neoplasm: Gal-1 can interact with TCR and CD45, affect CD45 phosphatase activity and the downstream signaling pathway of effector T cells, and selectively promote Treg amplification and secretion of IL-10, eventually leading to T-cell exhaustion and promoting tumor cell immune escape [117].